Novo Nordisk A/S Reduces Stake in Innate Pharma SA to 5.03%

Novo Nordisk A/S filed a Schedule 13G/A on April 10, 2026, disclosing a reduction in its stake in Innate Pharma SA (IPHA). As of the event date on March 31, 2026, Novo Nordisk reported beneficial ownership of 4,718,727 ordinary shares, representing 5.03% of the company's outstanding shares. This reflects a significant decrease from the previously reported holding of 7,333,778 shares, which accounted for 7.82% of the company. The filer, based in Denmark, maintains sole voting and dispositive power over the remaining shares. This filing marks the third amendment to their original Schedule 13G. The reduction in holdings suggests a partial divestment by the strategic investor, though they remain a significant shareholder above the 5% threshold. Innate Pharma is a biotechnology company headquartered in Marseille, France, specializing in immunotherapy.